Second Genome Inc:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Second Genome Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10587
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:27
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Second Genome Inc (Second Genome), formerly PhyloTech Inc, is a clinical stage pharmaceutical company that provides microbial research and drug discovery services. The company’s pipeline products include SGM-1019, a small molecule inhibitor targeting tissue injury and inflammation; and SG-2-0776, a therapeutic protein, which repairs damage caused to the intestinal epithelium. The company discovers, tests and validates product candidates through host-microbe interaction. It harnesses the proprietary microbiome drug discovery platform to develop novel medicines for a range of diseases including liver diseases, inflammatory bowel disease, metabolic diseases, immuno-oncology and central nervous system disorders. The company works in collaboration with other organizations to discover and develop microbiome-modulating medicines. Second Genome is headquartered in South San Francisco, California, the US.

Second Genome Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Second Genome Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Second Genome Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Second Genome Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Second Genome Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Second Genome Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Second Genome Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Second Genome Raises USD8.4 Million in Extended Series B Financing 11
Second Genome Raises USD42.6 Million in Series B Financing 12
Second Genome Raises US$6.5 Million In Extended Series A Financing 14
Partnerships 15
Second Genome Enters into Research Partnership with John Theurer Cancer Center 15
Second Genome Enters into Research Partnership with Stanford Cancer Institute, Ruprecht-Karls University Heidelberg and Roswell Park Cancer Comprehensive Cancer Center 16
Second Genome Enters into Research Partnership with Roswell Park Cancer Comprehensive Cancer Center and John Theurer Cancer Center 17
Second Genome Enters into Research Agreement with APC 18
Second Genome Enters into Agreement with Evotec 19
Second Genome Enters into Co-Development Agreement with Mayo Clinic Center for Individualized Medicine 20
Second Genome Enters Into Agreement With Janssen Biotech For Microbiome Drug Discovery 21
Second Genome Inc – Key Competitors 22
Second Genome Inc – Key Employees 23
Second Genome Inc – Locations And Subsidiaries 24
Head Office 24
Recent Developments 25
Corporate Communications 25
Sep 26, 2018: Second Genome Appoints Karim Dabbagh, Ph.D., as Chief Executive Officer 25
Government and Public Interest 26
Oct 03, 2017: Second Genome Launches Study of the Relationship Between Microbiome and Central Nervous System in Autism Spectrum Disorders 26
Appendix 27
Methodology 27
About GlobalData 27
Contact Us 27
Disclaimer 27

List of Tables
Second Genome Inc, Pharmaceuticals & Healthcare, Key Facts 2
Second Genome Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Second Genome Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Second Genome Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Second Genome Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Second Genome Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Second Genome Raises USD8.4 Million in Extended Series B Financing 11
Second Genome Raises USD42.6 Million in Series B Financing 12
Second Genome Raises US$6.5 Million In Extended Series A Financing 14
Second Genome Enters into Research Partnership with John Theurer Cancer Center 15
Second Genome Enters into Research Partnership with Stanford Cancer Institute, Ruprecht-Karls University Heidelberg and Roswell Park Cancer Comprehensive Cancer Center 16
Second Genome Enters into Research Partnership with Roswell Park Cancer Comprehensive Cancer Center and John Theurer Cancer Center 17
Second Genome Enters into Research Agreement with APC 18
Second Genome Enters into Agreement with Evotec 19
Second Genome Enters into Co-Development Agreement with Mayo Clinic Center for Individualized Medicine 20
Second Genome Enters Into Agreement With Janssen Biotech For Microbiome Drug Discovery 21
Second Genome Inc, Key Competitors 22
Second Genome Inc, Key Employees 23

List of Figures
Second Genome Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Second Genome Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Second Genome Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Second Genome Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Second Genome Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Second Genome Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Second Genome Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Second Genome Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Second Genome Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Obton AS:電力:M&Aディール及び事業提携情報
    Summary Obton A/S (Obton) is an investment company that offers management of assets within renewable energy. The company's investment process include screening process which inludes verification of prerequisites such as financial terms, amount of irradiation, power purchase agreement and feed-in tar …
  • Tethys Petroleum Ltd (TPL.H):石油・ガス:M&Aディール及び事業提携情報
    Summary Tethys Petroleum Ltd (Tethys) is an independent oil and gas exploration and production company. It focuses on projects in Central Asia and the Caspian Region. The company has a portfolio of assets, including existing oil and gas production, frontier high impact exploration and unconventional …
  • Fresenius Kidney Care-医療機器分野:企業M&A・提携分析
    Summary Fresenius Kidney Care (FMCNA) , formerly Fresenius Medical Care Holdings Inc, a subsidiary of Fresenius Medical Care AG & Co KGaA, is a provider of dialysis services and renal care products. The company’s dialysis products include hemodialysis; dialyzers, haemodialysis machines, FMiS medical …
  • CH&Co Group:企業の戦略・SWOT・財務分析
    CH&Co Group - Strategy, SWOT and Corporate Finance Report Summary CH&Co Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Surge Global Energy Inc:石油・ガス:M&Aディール及び事業提携情報
    Summary Surge Global Energy Inc (Surge Global) is an independent oil and gas exploration, production and trading company. The company acquires, finance and develops oil and gas properties. Its energy and metal commodities comprise natural gas, crude oil, coal, electricity, refined petroleum products …
  • NV Nederlandse Gasunie:企業の戦略的SWOT分析
    NV Nederlandse Gasunie - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • I-O Data Device, Inc. (6916):企業の財務・戦略的SWOT分析
    I-O Data Device, Inc. (6916) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Dechra Pharmaceuticals PLC:企業のM&A・事業提携・投資動向
    Dechra Pharmaceuticals PLC - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Dechra Pharmaceuticals PLC Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acqui …
  • Grupo Posadas Sab De Cv
    Grupo Posadas Sab De Cv - Strategy, SWOT and Corporate Finance Report Summary Grupo Posadas Sab De Cv - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Viavi Solutions Inc:企業の戦略・SWOT・財務分析
    Viavi Solutions Inc - Strategy, SWOT and Corporate Finance Report Summary Viavi Solutions Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Andrade Gutierrez SA:企業の戦略的SWOT分析
    Andrade Gutierrez SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Ophir Energy Plc (OPHR):石油・ガス:M&Aディール及び事業提携情報
    Summary Ophir Energy Plc (Ophir) is an independent upstream oil and gas company, which explores for and develops oil and gas properties. The company has working interests in assets across Africa and Asia. Ophir has assets in Tanzania, Equatorial Guinea, Kenya, Cote d’Ivoire, and Gabon in Africa; and …
  • E.ON SE (EOAN):企業の財務・戦略的SWOT分析
    E.ON SE (EOAN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the po …
  • TG Therapeutics Inc (TGTX):製薬・医療:M&Aディール及び事業提携情報
    Summary TG Therapeutics Inc (TG Therapeutics) is a biopharmaceutical company which acquires, develops and commercializes pharmaceutical products for the treatment of B-cell malignancies and autoimmune diseases. The company develops two therapies, namely, TG-1101 (ublituximab) and TGR-1202 for the tr …
  • Nuvaira Inc:医療機器:M&Aディール及び事業提携情報
    Summary Nuvaira Inc (Nuvaira), formerly Holaira Inc is an independent medical device company that strives to develop minimally invasive products for the treatment of obstructive lung diseases. It provides Lung Denervation System, a catheter-based system intended for asthma and chronic obstructive pu …
  • Banco Davivienda Sa:企業の戦略・SWOT・財務分析
    Banco Davivienda Sa - Strategy, SWOT and Corporate Finance Report Summary Banco Davivienda Sa - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Misonix Inc (MSON):医療機器:M&Aディール及び事業提携情報
    Summary Misonix Inc (Misonix) is a medical technology company that provides ultrasonic surgical devices for neurosurgical, spinal, advanced wound care and general surgery procedures. The company’s major products include BoneScalpel and BoneScalpel MIS cutting system; SonaStar surgical aspirator; Son …
  • United Spirits Ltd:企業の戦略・SWOT・財務情報
    United Spirits Ltd - Strategy, SWOT and Corporate Finance Report Summary United Spirits Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Bloomberg L.P.:企業の戦略・SWOT・財務分析
    Bloomberg L.P. - Strategy, SWOT and Corporate Finance Report Summary Bloomberg L.P. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Mangalore Chemicals & Fertilizers Ltd (MANGCHEFER):企業の財務・戦略的SWOT分析
    Summary Mangalore Chemicals & Fertilizers Ltd (MCFL), a subsidiary of Zuari Fertilisers and Chemicals Ltd, is a chemical company that manufactures and markets fertilizers, plant nutrition products, and plant protection chemicals. The company offers urea, di-ammonium phosphate, granulated fertilizers …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆